09 May 2018 Research
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades.
“We are excited at this breakthrough in the treatment for childhood leukaemia. CAR-T cell therapy gives those children who do not respond to chemotherapy treatment a real chance of a long-term cure. We welcome this significant step forward which will give hope to families whose children are affected by leukaemia.”
Dr Maria Gilleece, Director, Yorkshire Blood and Marrow Transplant Programme and a member of the Leukaemia UK Medical Panel.
Related posts
11 March 2022
Inquiry highlights the impact of COVID-19 on blood cancer services
A new report has recently been published, following an inquiry by the All-Party Parliamentary Group (APPG) on Blood Cancer and the APPG on Stem Cell Transplantation and Advanced Cellular Therapies, on the impact of Covid-19 on blood cancer services in the UK.
4 July 2022
Cancer charities unite in encouraging the Government to address crucial issues as part of their “War on Cancer”
In collaboration with our partners and as part of the One Cancer Voice group, Cancer 52 and Blood Cancer Alliance, we have called on the Government to take account of a wide range of recommendations as they finalise the 10-Year Cancer Plan to be announced later this year.
30 June 2023
New book ‘Bronty’s Battle Cry’ supports Leukaemia UK
‘Bronty’s Battle Cry,’ an inspiring new picture book written by award-winning children’s author and young person’s counsellor, Hannah Peckham, has recently launched and Leukaemia UK are delighted that some of…
17 April 2024
“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers
New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease. A family who was devastated when…